Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Nantkwest Inc    NK

NANTKWEST INC (NK)
Add to my list  
Mes dernières consult.
Most popular
Manage my lists
  Report  
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
07/16/2018 07/17/2018 07/18/2018 07/19/2018 07/20/2018 Date
3.12(c) 3.09(c) 3.02(c) 3.42(c) 3.29(c) Last
123 818 93 992 68 224 277 712 337 898 Volume
+0.32% -0.96% -2.27% +13.25% -3.80% Change
More quotes
Financials (USD)
Sales 2018 0,02 M
EBIT 2018 -117 M
Net income 2018 -117 M
Debt 2018 -
Yield 2018 -
Sales 2019 0,02 M
EBIT 2019 -130 M
Net income 2019 -130 M
Debt 2019 -
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales2018 13 353x
Capi. / Sales2019 13 353x
Capitalization 267 M
More Financials
Company
NantKwest, Inc. engages in the development of immunotherapies with a focus on harnessing the power of the innate immune system.It uses natural killer cells to treat cancer, infectious diseases, and inflammatory diseases.The firm operates through the following geographical segments: United States;... 
Read more
More about the company
Latest news on NANTKWEST INC
07/05NANTKWEST : Names Sonja Nelson Chief Financial Officer
AQ
07/05NANTKWEST : "Modified Nk-92 Cells for Treating Cancer" in Patent Application App..
AQ
06/28NANTKWEST : Names Sonja Nelson Chief Financial Officer
AQ
06/28NANTKWEST : "Modified Nk-92 Cells for Treating Cancer" in Patent Application App..
AQ
06/19NANTKWEST : Names Sonja Nelson Chief Financial Officer
BU
06/13NANTKWEST, INC. : Change in Directors or Principal Officers, Submission of Matte..
AQ
06/05NANTKWEST : to Present at Jefferies 2018 Global Healthcare Conference
BU
05/07NANTKWEST : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESU..
AQ
04/23NANTKWEST : to Present at Upcoming Science & Medicine Conferences
BU
04/18NANTKWEST, INC. (NASDAQ : NK) Files An 8-K Departure of Directors or Certain Off..
AQ
More news
Sector news : Bio Therapeutic Drugs
07/19Novartis, MorphoSys and Galapagos Shares Rise on News of Deal
DJ
07/09LONZA : restates 2017 figures after changing accounting standard
RE
07/03Sanofi beefs up diabetes pipeline to retrieve success
RE
06/29European stocks shrug off trade worries with quarterly gain
RE
06/29GILEAD SCIENCES : Rival Novartis, Gilead CAR-T therapies win European panel reco..
RE
More sector news : Bio Therapeutic Drugs
Latest Tweets
12:41aAnd here’s a photo from a month ago – that’s our new owner Patrick Soon-Shion..
15
07/19Los Angeles billionaire Patrick Soon-Shiong might not buy into D.C. United af.. 
07/13Dr. Patrick Soon-Shiong, the new owner of the Los Angeles Times, is the guest..
2
07/13#US, #NK to discuss return of #American #troops’ remains Sunday
1
07/13#BIFAN to shine light on #NK films, women's breakthroughs #Bucheon #NorthKore..
1
More tweets
Qtime:83
News from SeekingAlpha
06/19NantKwest names Sonja Nelson as CFO 
06/13New finance chief at NantKwest 
04/24BY THE NUMBERS : Healthcare Stocks With Big Cash Distributions 
04/02NantHealth Has Turned A Corner 
03/20Unum Therapeutics Updates Proposed IPO Terms 
Chart NANTKWEST INC
Duration : Period :
Nantkwest Inc Technical Analysis Chart | NK | US63016Q1022 | 4-Traders
Technical analysis trends NANTKWEST INC
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 3
Average target price 3,50 $
Spread / Average Target 6,4%
EPS Revisions
Managers
NameTitle
Patrick Soon-Shiong Chairman & Chief Executive Officer
Barry J. Simon President, Director & Chief Administrative Officer
Sonja Nelson Chief Financial Officer
Hans Georg Klingemann Vice President-Research & Development
Steven Gorlin Vice Chairman
Sector and Competitors
1st jan.Capitalization (M$)
NANTKWEST INC-26.73%267
GILEAD SCIENCES8.00%100 276
VERTEX PHARMACEUTICALS18.38%46 157
REGENERON PHARMACEUTICALS-2.35%38 776
GENMAB9.33%10 846
NEUROCRINE BIOSCIENCES, INC.33.30%9 279
4-traders.com :
About :
Stay Connected :
Partners :
Copyright © 2018 Surperformance. All rights reserved.